Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Nick Thatcher, Kevin Carroll, Tudor–Eliade Ciuleanu et al.|The Lancet|2005Cited by 2.1k
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung CancerFred R. Hirsch, Brian R. Holloway, Marileila Varella‐Garcia et al.|Journal of Clinical Oncology|2006Cited by 702
Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cellsAlex Y. Chang, Miao Wang|BMC Cancer|2013Cited by 75